Stromal Gene Signatures in Large-B-Cell Lymphomas
By G. Lenz, George W. Wright, S. Dave, Wenming Xiao, J. Powell, Huaqing Zhao, Wei Xu, Bruce K. Tan, N. Goldschmidt, J. Iqbal and 40 more. New England Journal of Medicine, 2008
1,778 citations recorded by the source corpus.
BACKGROUND The addition of rituximab to combination chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), or R-CHOP, has significantly improved the survival of patients with diffuse large-B-cell lymphoma. Whether gene-expression signatures correlate with survival after treatment of diffuse large-B-cell lymphoma is unclear. METHODS We profiled gene expression in pretreatment biopsy specimens from 181 patients with diffuse large-B-cell lymphoma who received CHOP and 233 patients with this disease who received R-CHOP. A multivariate gene-expression–based survival-predictor model derived from a training group was tested in a validation group. RESULTS A multivariate model created from three gene-expression signatures — termed “germinal-center B-cell,” “stromal-1,” and “stromal-2” — predicted survival both in patients who received CHOP and patients who received R-CHOP. The prognostically favorable stromal-1 signature reflected extracellular-matrix deposition and histiocytic infiltration. By contrast, the prognostically unfavorable stromal-2 signature reflected tumor blood-vessel density. CONCLUSIONS Survival after treatment of diffuse large-B-cell lymphoma is influenced by differences in immune cells, fibrosis, and angiogenesis in the tumor microenvironment.
Subfields: Neurology, Oncology, Pathology and Forensic Medicine
View Paper: https://www.semanticscholar.org/paper/8769e5235bef447edfd5fcbef9ed7665ff8c990f
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Neurology
In Oncology
In Pathology and Forensic Medicine
Citations in the corpus
- Environment-mediated drug resistance: a major contributor to minimal residual disease (2009, background): “In fact, recent work has demonstrated that stromal gene expression signatures can be a stronger predictor of clinical outcome in both haematological and epithelial malignancy than other factor”
- Google Goes Cancer: Improving Outcome Prediction for Cancer Patients by Network-Based Ranking of Marker Genes (2012, background): “In this case, a common choice is to split by the median survival time independently of the distribution (see for example [13,33]), which has the advantage of yielding two classes of equal size.”
- The 2008 WHO classification of lymphomas: implications for clinical practice and translational research (2009, neutral): “Further development of targeted therapies and recognition of additional markers of clinical behavior will likely result in additional modifications to this category in the future.(57,58)”
- Somatic mutation of EZH2 (Y641) in Follicular and Diffuse Large B-cell Lymphomas of Germinal Center Origin (2010, neutral): “A new human B-cell non-Hodgkin’s lymphoma cell line (Karpas 422) exhibiting both t (14;18) and t(4;11) chromosomal translocations.”
- Extracellular matrix remodeling in tumor progression and immune escape: from mechanisms to treatments (2023, background): “For example, specific stromal-related gene signature is correlated with prognosis of large-B-cell lymphoma patients receiving chemotherapy [553].”
- Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. (2012, methodology): “0 arrays (Affymetrix, Santa Clara, CA).(3) MYC mRNA expression was determined using log2 normalized expression values of probe set 202431_s_at and dichotomized into low versus high expression using a cutoff threshold determined by X-Tile (high, 9.”
- The secret ally: immunostimulation by anticancer drugs (2012, background): “The local expression of components and regulators of the extracellular matrix, the anti-angiogenic factor thrombospondin and genes of the monocytic lineage (for example, the genes encoding CCAAT/enhancer binding protein-α and colony stimulating factor 2 receptor-α, which are indicative of phagocytic”